CMS's Radical Experiment On Pricing Of Part B Drugs

By John McManus, president and founder, The McManus Group

Capitalizing on the growing vitriol directed at the pharmaceutical industry, the Obama administration unveiled a farreaching and aggressive “demonstration project” that would fundamentally change how physician-administered drugs are reimbursed by Medicare.

The administration proposes to scrap the current market-based “average sales price” (ASP) payment formula, which reimburses physicians and hospitals 106 percent of the ASP of a Part B drug (accounting for all discounts, rebates, and other price concessions).